top
Search terms
Results 1 - 9 of 9 - ordered by :
Ejhf

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document In ASCEND-HF, specific clinical variables including older age, ...

European Journal of Heart Failure, Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael ...

Date : 01/10/2013 Item size : 366395 bytes
Ehjournal

Background and scope of the problem Criteria have been established to define the occurrence of myocardial infarction (MI) or stroke in cardiovascular clinical trials, but a consensus definition has ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pitt, Bertram, Cleland, John G.F., Adams, Kirkwood F., Geller, Nancy L., Torp-Pedersen, Christian, Kirwan, Bridget-Anne, Follath, Ferenc

Date : 01/02/2008 Item size : 352597 bytes
Ehjournal

Bleeding risks are typically dose related, making selection of the optimal dose (or preferably, doses) to advance from phase II to III testing a critical step in drug development.1 Efficacy is ...

European Heart Journal, Verheugt, Freek W.A., Clemmensen, Peter, Mehran, Roxana, Agewall, Stefan, Pocock, Stuart J., Goldstein, Sidney, Torp-Pedersen, Christian, Simoons, Maarten L., Borer, Jeffrey ...

Date : 07/06/2013
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012 Item size : 369253 bytes
Ehjournal

Bleeding risks are typically dose related, making selection of the optimal dose (or preferably, doses) to advance from phase II to III testing a critical step in drug development.1 Efficacy is ...

European Heart Journal, Verheugt, Freek W.A., Clemmensen, Peter, Mehran, Roxana, Agewall, Stefan, Pocock, Stuart J., Goldstein, Sidney, Torp-Pedersen, Christian, Simoons, Maarten L., Borer, Jeffrey ...

Date : 07/06/2013
Ehjournal

Background and scope of the problem Criteria have been established to define the occurrence of myocardial infarction (MI) or stroke in cardiovascular clinical trials, but a consensus definition has ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pitt, Bertram, Cleland, John G.F., Adams, Kirkwood F., Geller, Nancy L., Torp-Pedersen, Christian, Kirwan, Bridget-Anne, Follath, Ferenc

Date : 01/02/2008
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012
Ejhf

Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure patients is characterized by a reduction in ...

European Journal of Heart Failure, Cowie, Martin R., Filippatos, Gerasimos S., Alonso Garcia, Maria de los Angeles, Anker, Stefan D., Baczynska, Anna, Bloomfield, Daniel M., Borentain, Maria, Bruins ...

Date : 01/06/2017 Item size : 89798 bytes
Ejhf

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document In ASCEND-HF, specific clinical variables including older age, ...

European Journal of Heart Failure, Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael ...

Date : 01/10/2013 Item size : 366163 bytes